PRODUCT INFORMATION



LSN3318839

Item No. 41245

CAS Registry No.: 2764704-18-7

Formal Name: 2-[1-[(1R)-1-(2,6-dichloro-3-

cyclopropylphenyl)ethyl]-1H-

imidazo[4,5-c]pyridin-6-yl]-αR-methyl-

benzeneacetic acid

MF: C26H23Cl2N3O2

FW: 480.4 **Purity:** ≥98% Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LSN3318839 is supplied as a solid. A stock solution may be made by dissolving the LSN3318839 in the solvent of choice, which should be purged with an inert gas. LSN3318839 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile.

Description

LSN3318839 is a positive allosteric modulator (PAM) of glucagon-like peptide 1 receptor (GLP-1R).¹ It potentiates increases in cAMP accumulation induced by the GLP-1R full agonist GLP-1 (9-36), but not the GLP-1R partial agonist GLP-1 (7-36), in INS-1 832/3 cells. LSN3318839 (1 and 3 μM) increases insulin levels in the presence, but not absence, of GLP-1 (9-36) in INS-1 832/3 cells under high-glucose conditions. It reduces blood glucose levels in glucose-dependent insulinotropic polypeptide receptor (GIPR) knockout mice in an oral glucose tolerance test when administered at a dose of 30 mg/kg and has an additive effect on reducing blood glucose levels in GIPR knockout mice when administered at 10 or 30 mg/kg in combination with the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.

Reference

1. Willard, F.S., Wainscott, D.B., Showalter, A.D., et al. Discovery of an orally efficacious positive allosteric modulator of the glucagon-like peptide-1 receptor. J. Med. Chem. 64(6), 3439-3448 (2021).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 06/18/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM